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A covalent cross-linking technique was used to bind iodinated interleukin-1 (ILl) alpha and beta to plasma proteins. One specific IL1 beta binding 
protein was observed, that when cross-linked to 1251-IL1 beta migrated to approximately 60 kDa on SDS-PAGE. The protein did not bind IL1 
alpha. The 43 -kDa protein was partially purified using a wheat germ agglutinin affinity column. The isolated factor again specifically bound IL1 
beta, and appeared to consist of single chain glycoprotein. The protein was heat stable and had a rapid association time with IL1 beta. This protein 
may be an important carrier molecule for IL1 beta in vivo. 
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1. INTRODUCTION 
Interleukin 1 (ILl) is a polypeptide produced by ac- 
tivated leukocytes and other cells. It mediates a wide 
range of biological activities relevant o host defence. It 
increases production of T and B lymphocyte growth 
factors and stimulates other cells involved in inflam- 
matory and immune responses. Additionally, it plays a 
role in connective tissue remodelling, haematopoiesis 
and is an important factor in the induction of fever and 
acute phase protein synthesis [l]. 
Two distinct forms of IL1 (IL1 alpha and IL1 beta) 
have been described [2]. Although the two peptides 
have only 26% homology, they compete for the same 
cellular receptor with equal affinity [3,4]. The murine 
IL1 receptor (ILlR) has recently been sequenced and 
cloned [5] and is a member of the immunoglobulin gene 
superfamily. The 319-amino-acid extracellular domain 
consists of two beta-pleated sheets connected by disul- 
phide bonds and seven potential N-linked glycosylation 
sites, which account for the described size heterogeneity 
of the ILlR. 
High expression of IL1 peptides appears to be a com- 
mon phenomenon in many inflammatory diseases 
leading to extensive tissue damage [a]. Therefore, 
regulatory pathways must exist to limit ILl-mediated 
responses. ILl-stimulated prostaglandin Ez production 
post-transcriptionally blocks monocyte expression of 
IL1 activity [7]. In addition, a large number of IL1 in- 
hibitory molecules have been described (reviewed by 
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Larrick [S]), although the mechanism of inhibition in 
most cases is largely unknown. The most highly char- 
acterised IL1 inhibitor described is produced by 
macrophages in response to GM-CSF [9] and immune 
complexes [lo] and has a molecular mass of approx- 
imately 26 kDa. This inhibitor blocks both IL1 alpha 
and IL1 beta but not TNF alpha binding to cell-surface 
receptors. Other proteins may control the distribution 
and bioavailability of IL1 in vivo by acting as carrier 
molecules. For example, treatment of plasma with tryp- 
sin or methylamine allows complex formation between 
alpha 2 macroglobulin and IL1 beta through disulphide 
bonding [ll]. 
In this paper we describe the presence of a novel IL1 
binding protein in normal human plasma. Unlike the 
previously known IL1 inhibitors and IL1 receptor pro- 
tein, the ILl-binding protein described here appears to 
have affinity specifically for IL 1 beta and does not bind 
IL1 alpha. 
2. MATERIALS AND METHODS 
2.1. Reagents 
Radioiodinated hr IL1 alpha and hr IL1 beta proteins were obtain- 
ed from Du Pont (NEN Products; Hertfordshire, England). IL1 
alpha was radioiodinated using the chloramine-T procedure to a 
specific activity of 90.4&i/pg (3.35 mBq//g). IL1 beta was labelled 
with Bolton Hunter reagent o a specific activity of 158 &i/fig (5.85 
mBq/pg). Cold human recombinant IL1 peptides were a gift from 
Biogen S.A., human recombinant TNF alpha was a gift from Dr 
Guenther Adolf (Ernst Boehringer Institut fur Arzneimittel For- 
schung, A-l 121 Wien, Austria). Covalent cross-linking reagents 
disuccinimidyl suberate (DSS), disuccinimidyl tartarate (DST) and 
ethylene glycolbis (succinamidyl succinate) (EGS) were obtained from 
Pierce and Warriner, Chester, England. 
2.2. Cell culture 
Murine 3T3 fibroblasts were cultured in RPMI-1640 containing 
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penicillin (100 U/ml), streptomycin (100 @g/ml), glutamine (2 mM) 
and 5% foetal calf serum (FCS; heat inactivated; 56°C 30 min). All 
cell culture reagents were obtained from Northumbria Biologicals 
(Northumb~a, England). 
A 
2.3. Covalent cross-linking and PAGE analysis 
Plasma or semi-purified protein (50 $1) was incubated overnight at 
4’C with 10 ng/ml of *z51-ILl alpha or IL1 beta, with or without 
lOO-fold excess of cold IL1 alpha, IL1 beta or TNF alpha. Subse- 
quently, covalent cross-linker, DSS, DST or EGS (final concentration 
1 mg/ml} freshly prepared in DMSO, was added and incubated at 4% 
for 30 min. Cross-linked complexes were identified in lOolo 
polyacrylamide gels according to Laemmli [12]. Samples to be tested 
under reducing conditions were treated with dithiothreitol (100 mM; 
DTT) and boiled for 10 min. 
92.5 > 
69 * 
46 * 
Monolayers of 3T3 fibroblasts in 25 cm3 flasks were incubated for 
4 h at 8’C with 1 ng/mI labelled IL1 alpha or IL1 beta in RPM1 1640 
containing 1% BSA, 0.1% sodium a&de and 20 mM Hepes, pH 7.4 
(binding buffer) in a final volume of 5 ml. Specificity of binding was 
controlled by the addition of excess cold cytokine as above. Unbound 
radioactivity was removed by washing three times in protein-free, ice- 
cold binding buffer. Five mililitres of this buffer was then added to 
each flask, cross-linker (DSS) was added to a final concentration of 
1 mg/ml and incubated on ice for 45 min. The cross-linker was then 
removed and replaced with 5 ml of quenching solution (10 mM Tris- 
HCl, pH 7.5, 1 mM EDTA). The cells were scraped using a rubber 
policeman into the buffer and centrifuged at 8OOxg for 10 min at 
4°C The cells were subsequently dissolved in 100,ul of 1% (w/v) SDS 
containing protease inhibitors PMSF (10 mM), EDTA (2 mM), 
pepstatin (2 mM) and 1,lO phenanthroline (2 mM). Samples were 
analysed by SDS-PAGE as described above. Iodinated cytokines were 
routinely assessed for self-association in cross-linking experiments. 
2 -4. Partial purification and characterisation 
IL1 binding proteins were partially purified using a wheat-germ ag- 
glutinin sepharose 6Ml3 column (Pharmacia LKB Biotechnology, 
England). Briefly, plasma was equilibrated by extensive dialysis 
against PBS and then loaded on the column using a flow rate of 
4 ml/h. The column was subsequently washed with PBS/O.3 M NaCI, 
PBS/IO% (v/v) ethylene glycol and finally PBS. Spe~fieally bound 
glycoproteins were then eluted from the column with PBS containing 
500 mM N-acetyl-glucosamine and 0.3 M NaCl. Two-millilitre frac- 
tions were collected and screened for IL1 bindig activity by covalent 
cross-linking. 
Heat stability of the partially purified binding protein was tested by 
incubating aliquots for 30 min at temperatures ranging from 4°C to 
70% Treated samples were then incubated with iodinated IL1 beta 
and cross-linked as previously described. Kinetics of binding of IL1 
beta to the protein was tested by incubating labelled cytokine with 
binding protein for various lengths of time at 4OC, room temperature 
or 37°C before cross-linking. 
Fig.1. 1251-ILl alpha (A) and ‘z51-ILl beta (B) cross-linked to plasma 
(lane 1) with excess cold IL1 alpha (lane 2), IL1 beta (lane 3) and TNF 
alpha (lane 4). 
200 * 
3. RESULTS 63) 
3.1. Covalent cross-linking 
Binding proteins were identified by cross-linking 
plasma previously incubated with iodinated IL1 . When 
IL1 alpha cross-linked to human plasma was analysed 
by SDS-PAGE, no specific binding was observable 
(fig,lA). A small amount of material that just entered 
the gel showed binding, but this appeared to be non- 
specific. To demonstrate that ‘z51-ILl alpha retained 
receptor binding activity, we cross-linked it to 3T3 
fibroblasts. Fig.2 shows that IL1 alpha specifically 
bound to its 80 KDa receptor on 3T3 cells. 
46) 
Fig.2. Cross-linking of iodinated IL1 atpha to 3T3 cells (lane 1) with 
excess cold IL1 alpha (lane 2), IL1 beta (lane 3) and TNF alpha (lane 
4). 
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Fig.3. Cross-linking of ‘251-IL1 beta to fractions eluted from a WGA 4. DISCUSSION 
column. 
In contrast when ‘251-ILl beta was cross-linked to 
plasma, an IL1 beta/protein complex was observed to 
migrate at approximately 60 kDa (fig.lB). This binding 
was displacable by lOO-fold excess of cold IL1 beta but 
not IL1 alpha or TNF alpha, and was seen with all three 
cross-linkers used. Some non-specific binding was also 
seen to high-molecular mass material. 
3.2. Purification and biochemical characterisation 
The 60 kDa IL1 beta/binding protein complex 
migrated as a broad band from 50-70 kDa suggesting 
the possibility of variable glycosylation. We therefore 
used lectin affinity chromatography for partial purifi- 
cation of the binding protein. Experiments revealed 
that the binding protein could be specifically eluted 
from a wheat germ agglutinin (WGA) affinity column. 
The result of this purification is shown in fig.3. The bin- 
ding protein eluted from the column with ZV-acetyl 
glucosamine and when cross-linked to “‘I-IL1 beta, 
migrated at the same molecular mass as the unpurified 
plasma protein. The specificity of this protein for IL1 
beta was retained (fig.4) as it failed to bind 1251-IL1 
alpha. Further 1251-IL1 beta binding was only competed 
by lOO-fold excess cold IL1 beta. Separation of plasma 
on the WGA column resulted in a 25-fold purification. 
SDS-PAGE analysis of plasma cross-linked with 
iodinated ILls shows an IL1 beta/binding protein com- 
plex of molecular mass 60 kDa suggesting the presence 
of a 43 kDa factor in human plasma capable of specific 
association with IL1 beta and not IL1 alpha. Partial 
purification using a WGA column isolated a protein 
that bound IL1 beta and was not affected by reducing 
conditions, suggesting the presence of a single polypep- 
tide chain. The binding factor is thought to be a heat- 
stable glycoprotein with rapid association kinetics with 
IL1 beta. A high-molecular-mass factor is also seen to 
bind both labelled IL1 alpha and IL1 beta; this appears 
to be non-specific. 
Vairous factors have been described as IL1 inhibitors 
[8], most of which are assayed by their ability to in- 
terfere with the co-mitogenic activity of IL1 on thymo- 
cytes. A well-characterised 23 kDa inhibitor affects 
both IL1 alpha and IL1 beta stimulation of fibroblast 
prostaglandin production and blocks iodinated IL1 
alpha binding to its receptor [9]. Uromodulin, an im- 
munosuppressive glycoprotein, inhibits ILl-induced T 
cell proliferation. This activity depends on intact 
glycosylation and it appears that IL1 itself binds to 
uromodulin through lectin-like binding [13]. It is 
unlikely that either of these inhibitors are comparable 
to the binding protein described here, due to molecular 
mass and specificity differences. A granulocyte-derived 
45-70 kDa molecule [14] and a 40 kDa immunosup- 
pressive protein from epidermal cells have been de- 
scribed to inhibit ILl-induced thymocyte co-mito- 
genesis and fibroblast proliferation [ 151. However, 
none of these factors have been shown to be specific for 
either IL1 alpha or IL1 beta alone. 46, 
30, 
2l> 
1 2345 6 1 2345 6 
Fig.4. ‘251-IL1 alpha (A) and ‘*%ILl beta (B) cross-linked to fraction 
8 of the affinity column (lane l), with excess cold IL1 alpha (lane 2), 
IL1 beta (lane 3) and TNF alpha (lane 4) and also under reducing con- 
ditions (lane 5) iodinated proteins are also cross-linked to plasma 
(lane 6). 
Reducing SDS-PAGE resulted in the 12’1-IL1 beta/ 
binding protein complex migrating at the same mole- 
cular mass as in non-reducing conditions (fig.4). Heat 
treatment of semi-purified binding protein before 
cross-linking showed that the ‘251-IL1 beta binding 
ability was retained even at 70°C (data not shown). In- 
cubation of labelled IL1 beta with binding protein for 
various lenghts of time at 4”C, room temperature and 
37°C indicated that rapid association occurred, with 
maximal binding after 30 min at 37°C (data not 
shown). 
Some groups have suggested that the proteinase in- 
hibitor alpha 2 macroglobulin (alpha 2M) may, in an 
activated form, bind ILl, accounting for its various im- 
munosuppressive actions in vitro [ 111. Activated alpha 
2M has been found at high levels in synovial fluid of 
rheumatoid arthritis patients and also acts as a binding 
protein for IL6 [16]. Alpha 2M may account for the 
high-molecular-mass factor seen to bind non-speci- 
fically both IL1 alpha and IL1 beta in the present study. 
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The 43 kDa specific IL1 beta binding protein describ- 
ed here may represent a solubilised form of the IL1 
receptor, but a recombinant form of the murine ILlR 
comprising only the extracellular domain retains equal 
affinity for IL1 alpha and beta [17]. Radiolabelled IL1 
beta has a half-life in vivo of approximately 5-10 min 
following i.v. injection [18]. Despite the presence of 
IL1 R on many cells circulating in the blood, IL 1 beta is 
almost entirely associated with the plasma. Distribution 
studies indicate that apart from the liver and kidneys, 
IL1 beta distributes into all tissues to approximately the 
same extent. The specific binding protein described here 
may therefore act as a carrier molecule for IL1 in body 
fluids and may be an important determinant of tissue 
distribution and bioavailability in vivo. It may also ex- 
plain in part the difficulty of measuring IL1 in body 
fluids. With the increasing interest in the potential of 
recombinant IL1 beta as a therapeutic molecule or as a 
target for pharmacological intervention, it becomes im- 
portant to understand the factors that control its handl- 
ing in vivo. 
Acknowledgements: We wish to thank Miss Anne S. Mitchell for the 
preparation of the manuscript. This work was supported by a grant 
from the Nuffield Foundation (Oliver Bird Fund for Research into 
Rheumatism) and by the Mary E. McKinnell Trust (Fellowship to 
J.A.S.). 
REFERENCES 
[l] Dinarello, C.A. (1989) Adv. Immunol. 44, 153-205. 
PI 
131 
141 
[51 
El 
[71 
181 
PI 
[lOI 
1111 
1121 
[I31 
1141 
u51 
1161 
1171 
1181 
March, C.J., Mosley, B., Larsen, A., Cerretti, D.P., Braedt, 
G., Price, V., Gillis, S., Henney, C.S., Kronheim, S.R., 
Grabstein, K., Conlon, P.J., Hopp, T.P. and Cosman, D. 
(1985) Nature 315, 641-647. 
Bird, T.A. and Saklatvala, J. (1986) Nature, 324, 263-266. 
Dower, S.K., Kronheim, S.R., Hopp, T.P., Cantrell, M., 
Deeley, M., Gillis, S., Henney, C.S. and Urdal, D.L. (1986) 
Nature, 324, 266-268. 
Sims, J.E., March, C. J., Cosman, D., Widmer, M.B., 
MacDonald, H.R., McMahan, C.J., Grubin, C., Wignall, J.M., 
Jackson, J.L., Call, S.M., Friend, D., Alpert, A.R., Gillis, S., 
Urdal, D.L. and Dower, S.K. (1988), Science 241, 585-589. 
Duff, G.W. (1989) Lancet, June 24, 1432-1435. 
Knudsen, P.J., Dinarello, C.A. and Strom, T.B. (1986) J. 
Immunol., 137, 3189-3194. 
Larrick, J.W. (1989) Immunol. Today, 10, 61-66. 
Seckinger, P., Williamson, K., Balavoine, J.F., Mach, B., 
Mazzei, G., Shaw, A. and Dayer, J.-M. (1987) J. Immunol. 139, 
1541-1545. 
Arend, W.P., Joslin, F.G. and Massoni, R.J. (1985) J. 
Immunol., 134, 3868-3875. 
Borth, W. and Lugar, T.A. (1989) J. Biol. Chem. 264, 
5818-5825. 
Laemmli, U.K. (1970) Nature, 227, 680-685. 
Muchmore, A.V. and Decker, J.M. (1987) J. Immunol., 138, 
2541-2546. 
Tiku, K., Tiku, M.L., Liu, S. and Skosey, J.L. (1986) J. 
Immunol., 136, 3686-3692. 
Schwarz, T., Urbanska, A., Gschnait, F. and Luger, T.A. 
(1987) J. Immunol., 138, 1457-1463. 
Matsuda, T., Hirano, T., Nagasawa, S. and Kishimoto, T. 
(1989) J. Immunol., 142, 148-152. 
Dower, S.K., Wignall, J.M., Schooley, K., McMahan, C. J., 
Jackson, J.L., Prickett, KS., Lupton, S., Cosman, D. and 
Sims, J.E. (1989) J. Immunol. 142, 4314-4320. 
Newton, R.C., Uhl, J., Covington, M. and Back, 0. (1988) 
Lymphokine Res. 7, 207-216. 
216 
